Patent ID: 6472373
Filing Date: 2002-10-29
Classification: A61K,Y10S

Abstract:
A method of treating antiviral treatment naive patients having chronic hepatitis C (â€œHCVâ€ ) infection comprising identifying antiviral treatment naive patients having HCV genotype 1 and an initial viral load of greater than 2 million copies/ mL of serum HCV-RNA as measured by HCV-RNA/ quantitative Polymerase Chain Reaction (â€œqPCRâ€ ) and then administering to said antiviral treatment naÃ¯ve patients a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of about 40 to about 50 weeks and identifying antiviral treatment naive patients having an HCV genotype 1 and an initial viral load of less than or equal to 2 million copies/ mL of serum HCV-RNA as measured by HCV-RNA/ quantitative Polymerase Chain Reaction (â€œqPCRâ€ ) and then administering to said antiviral treatment naive patients a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of about 20 to about 24 weeks.